Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
Aleve PM is a fixed-dose combination of naproxen sodium (an NSAID) and diphenhydramine HCl (a first-generation antihistamine with sedating properties) in oral tablet form. It is indicated for nighttime pain relief, leveraging the analgesic/anti-inflammatory action of naproxen with the sleep-aid properties of diphenhydramine. The product targets consumers seeking combined pain management and sleep support for conditions like minor arthritis pain, backache, and headache.
Peak lifecycle stage suggests stable revenue but potential pressure from generic and OTC alternatives; brand team likely optimized for steady-state maintenance rather than growth investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Aleve PM offers career opportunities primarily in commercial, marketing, and sales functions focused on OTC consumer engagement and retail channel management. This is a stable, peak-stage product ideal for professionals seeking to optimize brand share in a mature market rather than drive innovation or new indications.
Worked on ALEVE PM at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo